Investor Relations Overview

Juniper Pharmaceuticals (Nasdaq: JNP) is developing therapeutics that address unmet and underserved medical needs in women's health. Our current product pipeline leverages our highly differentiated intravaginal ring ("IVR") technology with new formulations of existing pharmaceuticals, which we expect will offer multiple benefits to patients. Current 505(b)(2) candidates include:


  • JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women;
  • JNP-0201, a combination estradiol + progesterone IVR for hormone replacement therapy; and,
  • JNP-0301, a natural progesterone IVR for the prevention of preterm birth.


We are leveraging the in-house pharmaceutical development, clinical trial supply manufacturing, and analytical capabilities of Juniper Pharma Services (“JPS”) to advance this internal product pipeline while also providing valuable intellectual property-related consultative and clinical trial manufacturing services to our pharmaceutical industry customers.

Our R&D programs are supported by cash flow generated by Crinone® (progesterone gel) and JP. We supply Crinone to Merck KGaA, Darmstadt, Germany, for sale outside the U.S. CRINONE® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and Allergan, Inc. in the U.S.

Stock Quote

Copyright Nasdaq. Minimum 15 minutes delayed.